Immunotherapy in breast cancer: an overview of current strategies and perspectives

Immunotherapy in breast cancer: an overview of current strategies and perspectives

Recent progress in immunobiology has led the way to successful host immunity enhancement against breast cancer. In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early settin...

Full description

Saved in:
Bibliographic Details
Published in:NPJ breast cancer Vol. 9; no. 1; p. 7
Main Authors: Debien, Véronique, De Caluwé, Alex, Wang, Xiaoxiao, Piccart-Gebhart, Martine, Tuohy, Vincent K., Romano, Emanuela, Buisseret, Laurence
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 13-02-2023
Nature Publishing Group
Nature Portfolio
Subjects:
631/67/1347
692/4028/67/1347
Antigens
Biomarkers
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cancer Research
Cancer therapies
Cancer vaccines
Cell Biology
Chemotherapy
Clinical trials
Cytotoxicity
Human Genetics
Immunotherapy
Ligands
Lymphocytes
Medical prognosis
Medical research
Metastasis
Monoclonal antibodies
Oncology
Response rates
Review
Review Article
Tumors
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Recent progress in immunobiology has led the way to successful host immunity enhancement against breast cancer. In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early setting phase 3 clinical trials. These encouraging results lead to the first approvals of immune checkpoint inhibitors in triple-negative breast cancer and thus offer new therapeutic possibilities in aggressive tumors and hard-to-treat populations. Furthermore, several ongoing trials are investigating combining immunotherapies involving immune checkpoint inhibitors with conventional therapies and as well as with other immunotherapeutic strategies such as cancer vaccines, CAR-T cells, bispecific antibodies, and oncolytic viruses in all breast cancer subtypes. This review provides an overview of immunotherapies currently under clinical development and updated key results from clinical trials. Finally, we discuss the challenges to the successful implementation of immune treatment in managing breast cancer and their implications for the design of future clinical trials.
AbstractList Recent progress in immunobiology has led the way to successful host immunity enhancement against breast cancer. In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early setting phase 3 clinical trials. These encouraging results lead to the first approvals of immune checkpoint inhibitors in triple-negative breast cancer and thus offer new therapeutic possibilities in aggressive tumors and hard-to-treat populations. Furthermore, several ongoing trials are investigating combining immunotherapies involving immune checkpoint inhibitors with conventional therapies and as well as with other immunotherapeutic strategies such as cancer vaccines, CAR-T cells, bispecific antibodies, and oncolytic viruses in all breast cancer subtypes. This review provides an overview of immunotherapies currently under clinical development and updated key results from clinical trials. Finally, we discuss the challenges to the successful implementation of immune treatment in managing breast cancer and their implications for the design of future clinical trials.
Abstract Recent progress in immunobiology has led the way to successful host immunity enhancement against breast cancer. In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early setting phase 3 clinical trials. These encouraging results lead to the first approvals of immune checkpoint inhibitors in triple-negative breast cancer and thus offer new therapeutic possibilities in aggressive tumors and hard-to-treat populations. Furthermore, several ongoing trials are investigating combining immunotherapies involving immune checkpoint inhibitors with conventional therapies and as well as with other immunotherapeutic strategies such as cancer vaccines, CAR-T cells, bispecific antibodies, and oncolytic viruses in all breast cancer subtypes. This review provides an overview of immunotherapies currently under clinical development and updated key results from clinical trials. Finally, we discuss the challenges to the successful implementation of immune treatment in managing breast cancer and their implications for the design of future clinical trials.
ArticleNumber 7
Author Debien, Véronique
Piccart-Gebhart, Martine
Tuohy, Vincent K.
De Caluwé, Alex
Wang, Xiaoxiao
Buisseret, Laurence
Romano, Emanuela
Author_xml – sequence: 1
  givenname: Véronique
  surname: Debien
  fullname: Debien, Véronique
  organization: Academic Trials Promoting Team, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet
– sequence: 2
  givenname: Alex
  orcidid: 0000-0001-5989-7017
  surname: De Caluwé
  fullname: De Caluwé, Alex
  organization: Radiotherapy Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB)
– sequence: 3
  givenname: Xiaoxiao
  surname: Wang
  fullname: Wang, Xiaoxiao
  organization: Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB)
– sequence: 4
  givenname: Martine
  orcidid: 0000-0001-9068-8504
  surname: Piccart-Gebhart
  fullname: Piccart-Gebhart, Martine
  organization: Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB)
– sequence: 5
  givenname: Vincent K.
  surname: Tuohy
  fullname: Tuohy, Vincent K.
  organization: Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, and Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of CWRU
– sequence: 6
  givenname: Emanuela
  orcidid: 0000-0002-1574-5545
  surname: Romano
  fullname: Romano, Emanuela
  organization: Centre for Cancer Immunotherapy, Medical Oncology Department, INSERM U932, Institut Curie, PSL Research University
– sequence: 7
  givenname: Laurence
  orcidid: 0000-0002-3751-0819
  surname: Buisseret
  fullname: Buisseret, Laurence
  email: laurence.buisseret@bordet.be
  organization: Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36781869$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1TAQhi1URC_0BVigSGzYBHyJbyyQqorCkSohIVhbjjM-zVFiH-zkoL49TlNKy4LFyJbnn88z9n-KjkIMgNArgt8RzNT73BBOWY2XwByrmj1DJ5TJpm6ElEeP9sfoPOcdxpg0QmlOXqBjJqQiSugT9G0zjnOI0w0ku7-t-lC1CWyeKmeDg_ShsqGKB0iHHn5V0VduTgnCVOUp2Qm2PeSi6Ko9pLwHN_UHyC_Rc2-HDOf36xn6cfXp--WX-vrr583lxXXteIOnuvWt9SB1Yy12zHvfMio9k9Z5SRSVILzyAnPLnRLeN7az0mKtWi1BlSJ2hjYrt4t2Z_apH226NdH25u4gpq2xaerdAEYKIjxTQDUXDaNdAWLPO-dJIxnVtLA-rqz93I7QuTJissMT6NNM6G_MNh6M1pRLoQvg7T0gxZ8z5MmMfXYwDDZAnLOhUgpOpCasSN_8I93FOYXyVIuKKynVXUd0VbkUc07gH5oh2CwOMKsDDF5icYBZ0K8fj_FQ8ue_i4CtglxSYQvp793_wf4G4FC_Jg
CitedBy_id crossref_primary_10_3390_biomedicines12040895
crossref_primary_10_1016_j_lfs_2024_122525
crossref_primary_10_1016_j_mam_2024_101254
crossref_primary_10_7759_cureus_62338
crossref_primary_10_1016_j_ctrv_2024_102769
crossref_primary_10_1186_s12943_023_01805_y
crossref_primary_10_1136_jitc_2023_007279
crossref_primary_10_1016_j_critrevonc_2024_104355
crossref_primary_10_1007_s10072_024_07350_w
crossref_primary_10_1186_s12943_024_01990_4
crossref_primary_10_1038_s41598_024_51361_8
crossref_primary_10_1002_adbi_202400140
crossref_primary_10_1080_21691401_2023_2270023
crossref_primary_10_1007_s10549_024_07286_x
crossref_primary_10_1016_j_bmc_2023_117586
crossref_primary_10_1016_j_soncn_2023_151553
crossref_primary_10_1093_ckj_sfad141
crossref_primary_10_1093_jleuko_qiad144
crossref_primary_10_1002_smll_202306766
crossref_primary_10_1007_s11912_024_01528_3
crossref_primary_10_2340_1651_226X_2024_33008
crossref_primary_10_3390_cancers16111973
crossref_primary_10_3390_biomedicines11123164
crossref_primary_10_1080_19768354_2024_2315950
crossref_primary_10_3390_biom13091306
crossref_primary_10_1016_j_jbo_2023_100505
crossref_primary_10_1007_s12282_024_01596_0
crossref_primary_10_1080_07357907_2023_2267675
crossref_primary_10_1007_s10585_023_10246_2
crossref_primary_10_1021_acs_biomac_3c01373
crossref_primary_10_1073_pnas_2316763120
crossref_primary_10_3389_fimmu_2024_1385484
crossref_primary_10_1158_1535_7163_MCT_23_0303
crossref_primary_10_1016_j_ccr_2023_215507
crossref_primary_10_1166_sam_2023_4438
crossref_primary_10_3390_ijms24076422
crossref_primary_10_1007_s00262_024_03699_1
crossref_primary_10_3390_ijms241713269
crossref_primary_10_1097_MD_0000000000036957
crossref_primary_10_1080_21645515_2024_2335728
crossref_primary_10_1080_10799893_2024_2325353
crossref_primary_10_3390_cancers15184479
crossref_primary_10_1186_s11671_024_03985_y
crossref_primary_10_1039_D4BM00286E
crossref_primary_10_1186_s13287_024_03717_0
crossref_primary_10_3390_cancers15153801
crossref_primary_10_1021_acs_chemmater_3c02472
crossref_primary_10_3390_cancers15194839
crossref_primary_10_1038_s41467_023_42744_y
crossref_primary_10_1080_2162402X_2023_2223094
crossref_primary_10_3390_cancers16040747
crossref_primary_10_1021_acsapm_2c02087
crossref_primary_10_3390_ijms25063354
crossref_primary_10_1038_s41388_024_03002_7
crossref_primary_10_1016_j_slasd_2023_08_008
crossref_primary_10_1038_s41416_023_02512_7
crossref_primary_10_3389_fphar_2023_1259628
crossref_primary_10_3390_ijms242015332
crossref_primary_10_4048_jbc_2023_26_e45
crossref_primary_10_1186_s12967_024_05281_w
crossref_primary_10_1002_adhm_202400046
crossref_primary_10_3390_futurepharmacol3040043
crossref_primary_10_1021_acs_bioconjchem_3c00519
crossref_primary_10_3390_cancers15112933
crossref_primary_10_1002_adfm_202401749
crossref_primary_10_1016_j_isci_2023_107556
crossref_primary_10_1016_j_biopha_2024_116559
crossref_primary_10_1016_j_prp_2024_155144
crossref_primary_10_1002_jso_27725
crossref_primary_10_3892_ijo_2024_5623
crossref_primary_10_1038_s41591_024_03088_2
crossref_primary_10_21294_1814_4861_2024_23_3_64_72
crossref_primary_10_1016_j_esmoop_2024_102964
crossref_primary_10_3389_fphar_2023_1244597
crossref_primary_10_1016_j_esmoop_2024_102247
crossref_primary_10_1016_j_asej_2024_102734
crossref_primary_10_1186_s12967_023_04640_3
crossref_primary_10_3390_cancers16050911
crossref_primary_10_2147_BCTT_S424624
crossref_primary_10_1080_2162402X_2024_2327692
Cites_doi 10.1136/jitc-2020-001511
10.1136/jitc-2021-002597
10.1186/s12935-021-02187-1
10.1038/nrc1167
10.1517/14712598.2012.725719
10.3390/cancers8060056
10.1093/jnci/djz208
10.1200/JCO.2020.38.15_suppl.1015
10.1038/s41577-021-00547-6
10.1158/2159-8290.CD-17-0915
10.1016/j.annonc.2020.01.072
10.1016/S1470-2045(19)30026-9
10.1016/j.bja.2019.11.034
10.1016/j.annonc.2021.05.355
10.1158/1078-0432.CCR-07-4756
10.1016/S0140-6736(20)31953-X
10.1016/j.ccell.2016.02.006
10.1016/S1470-2045(20)30465-4
10.1016/j.cell.2021.09.020
10.1038/nrc3245
10.1016/j.annonc.2020.05.015
10.1056/NEJMoa1809615
10.3389/fonc.2020.605633
10.1001/jamaoncol.2019.1029
10.1007/s10549-017-4130-y
10.1200/JCO.2021.39.15_suppl.506
10.1186/s12885-021-08601-1
10.1097/CJI.0b013e3182280db1
10.1016/S1470-2045(15)00007-8
10.1016/j.annonc.2021.05.800
10.18632/oncotarget.21959
10.1200/JCO.2016.34.15_suppl.1086
10.1001/jamaoncol.2020.3524
10.1093/annonc/mdz158
10.1056/NEJMoa2112651
10.1158/1538-7445.SABCS20-PD14-07
10.1136/esmoopen-2017-000255
10.1038/s41379-020-0544-x
10.1056/NEJMoa2105215
10.1093/annonc/mdu211
10.1016/j.annonc.2021.03.212
10.1016/j.annonc.2021.05.801
10.1093/annonc/mdw150
10.1016/j.semcancer.2018.02.005
10.1200/JCO.2018.36.5_suppl.206
10.1016/j.ejca.2021.03.010
10.1158/1078-0432.CCR-19-1773
10.1016/S1470-2045(17)30074-8
10.1016/S0140-6736(20)32531-9
10.1158/2159-8290.CD-20-1638
10.2217/imt.15.81
10.1200/JCO.2015.64.8931
10.1200/JCO.21.02772
10.3390/cancers13153875
10.3389/fonc.2020.581801
10.1016/S1470-2045(20)30754-3
10.1158/2159-8290.CD-18-1218
10.1158/0008-5472.CAN-12-1699
10.1158/2326-6066.CIR-17-0189
10.1016/j.annonc.2022.03.108
10.1093/annonc/mdz395
10.1200/JCO.2021.39.15_suppl.1006
10.1038/nrclinonc.2015.215
10.1158/2159-8290.CD-16-0577
10.1158/1538-7445.SABCS21-P2-13-07
10.1001/jamaoncol.2019.6650
10.1158/1535-7163.MCT-20-0385
10.1016/j.annonc.2020.11.022
10.1016/S1470-2045(20)30324-7
10.1016/j.ejca.2021.05.035
10.1158/1538-7445.SABCS16-P6-10-03
10.1001/jamaoncol.2018.4224
10.1038/ncomms10499
10.2217/fon-2019-0059
10.1200/JCO.2022.40.16_suppl.TPS611
10.1056/NEJMoa1612645
10.1186/gb-2007-8-8-r157
10.1158/1078-0432.CCR-18-2867
10.1016/S0140-6736(13)62422-8
10.3389/fimmu.2018.00947
10.1124/mi.10.4.2
10.1038/s41571-019-0297-y
10.1001/jamaoncol.2018.5152
10.1158/1078-0432.CCR-21-2260
10.1016/S1470-2045(18)30812-X
10.1038/s41523-022-00482-2
10.1056/NEJM198704093161501
10.1136/jitc-2020-SITC2020.0320
10.1016/j.trecan.2020.09.004
10.1038/s41591-020-01189-2
10.1200/JCO.21.02170
10.1080/14712598.2021.1922665
10.1056/NEJMoa2202809
10.1200/JCO.2019.37.15_suppl.TPS601
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
NPM
AAYXX
CITATION
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s41523-023-00508-3
DatabaseName SpringerOpen
PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest_Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database (Proquest) (PQ_SDU_P3)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
PubMed


Publicly Available Content Database
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2374-4677
EndPage 7
ExternalDocumentID oai_doaj_org_article_7616f38e2956432d86f0f5dcf1473292
10_1038_s41523_023_00508_3
36781869
Genre Journal Article
Review
GroupedDBID 0R~
3V.
53G
5VS
7X7
8FI
8FJ
AAJSJ
ABUWG
ACGFS
ACSMW
ADBBV
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCNDV
BENPR
BPHCQ
BVXVI
C6C
CCPQU
EBLON
EBS
EMOBN
FYUFA
GROUPED_DOAJ
HMCUK
HYE
M~E
NAO
NO~
OK1
PGMZT
PIMPY
PQQKQ
PROAC
RNT
RPM
SNYQT
UKHRP
NPM
AAYXX
CITATION
7XB
8FK
AZQEC
DWQXO
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c540t-bfbafe794aa0c3fffb327f37acf71827e6f8f605a5c86ff4ada7a098b97e84aa3
IEDL.DBID RPM
ISSN 2374-4677
IngestDate Tue Oct 22 15:14:35 EDT 2024
Tue Sep 17 21:33:59 EDT 2024
Sat Oct 05 05:19:37 EDT 2024
Thu Oct 10 18:26:31 EDT 2024
Thu Nov 21 23:27:03 EST 2024
Sat Sep 28 08:15:45 EDT 2024
Fri Oct 11 20:46:11 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-bfbafe794aa0c3fffb327f37acf71827e6f8f605a5c86ff4ada7a098b97e84aa3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0001-9068-8504
0000-0002-3751-0819
0000-0001-5989-7017
0000-0002-1574-5545
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925769/
PMID 36781869
PQID 2775877892
PQPubID 2041925
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_7616f38e2956432d86f0f5dcf1473292
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9925769
proquest_miscellaneous_2776517913
proquest_journals_2775877892
crossref_primary_10_1038_s41523_023_00508_3
pubmed_primary_36781869
springer_journals_10_1038_s41523_023_00508_3
PublicationCentury 2000
PublicationDate 2023-02-13
PublicationDateYYYYMMDD 2023-02-13
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-13
  day: 13
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: United States
PublicationTitle NPJ breast cancer
PublicationTitleAbbrev npj Breast Cancer
PublicationTitleAlternate NPJ Breast Cancer
PublicationYear 2023
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Dieci (CR41) 2022; 28
Masuda (CR49) 2017; 376
Esteva, Hubbard-Lucey, Tang, Pusztai (CR8) 2019; 20
You (CR59) 2021; 21
Dees, Ganesan, Singh, Grewal (CR80) 2020; 19
Emens (CR86) 2021; 39
Loibl (CR38) 2021; 39
Schmid (CR15) 2018; 379
O’Shaughnessy (CR64) 2016; 34
Vinayak (CR30) 2019; 5
Tutt (CR50) 2021; 384
CR78
Miles (CR17) 2021; 32
Clifton, Mittendorf, Peoples (CR54) 2015; 7
Domchek (CR29) 2020; 21
Gray, Yan, Kast (CR71) 2010; 10
Yuan (CR25) 2021; 154
Nanda (CR40) 2020; 6
Thomas (CR62) 2018; 9
Aldea (CR91) 2021; 11
Emens (CR51) 2021; 9
Huober (CR48) 2022; 40
Mittendorf (CR57) 2019; 25
Deng (CR23) 2018; 8
Loibl (CR36) 2019; 30
Stevens, Vachon, Couch (CR73) 2013; 73
Tolaney (CR94) 2020; 38
Rugo (CR24) 2022; 8
Tuohy (CR72) 2016; 8
Voorwerk (CR95) 2021; 32
Ghisoni (CR52) 2021; 149
Seymour (CR89) 2017; 18
Cortazar (CR32) 2014; 384
Kimura, Finn (CR67) 2013; 13
Goel (CR22) 2016; 29
Sharabi, Lim, DeWeese, Drake (CR44) 2015; 16
Lam (CR61) 2021; 13
Higgins (CR63) 2017; 162
Nanda (CR11) 2017; 77
Winer (CR13) 2021; 22
Fuentes-Antrás (CR77) 2020; 10
Adams (CR14) 2019; 5
CR42
CR84
CR83
Solinas (CR10) 2017; 2
Gatti-Mays (CR65) 2020; 10
De Caluwé (CR45) 2021; 21
Emens (CR16) 2021; 32
Hutchinson (CR31) 2020; 26
Nanda (CR9) 2016; 34
Desmedt (CR3) 2008; 14
Morad, Helmink, Sharma, Wargo (CR92) 2021; 184
Pantelidou (CR28) 2019; 9
Mittendorf (CR56) 2016; 27
Emens (CR27) 2020; 21
Liu (CR33) 2016; 6
CR58
Schmid (CR34) 2022; 386
Jerusalem (CR46) 2022; 33
Bareche (CR5) 2020; 112
Karn (CR7) 2020; 31
Emens (CR12) 2019; 5
Morris, Neelapu, Giavridis, Sadelain (CR81) 2022; 22
Chung (CR66) 2018; 36
Park (CR90) 2019; 30
CR93
Tolaney (CR21) 2020; 6
Bedard (CR85) 2022; 82
Mittendorf (CR35) 2020; 396
Rosenberg (CR76) 1987; 316
Maus (CR82) 2020; 8
Reisenbichler (CR88) 2020; 33
Weber (CR68) 2011; 34
Savas (CR1) 2016; 13
Teschendorff, Miremadi, Pinder, Ellis, Caldas (CR2) 2007; 8
Cortes (CR19) 2020; 396
Tchou (CR79) 2017; 5
Dudley, Rosenberg (CR74) 2003; 3
Wang (CR60) 2016; 7
Allard (CR4) 2018; 52
Huober (CR47) 2021; 32
Cortés (CR18) 2019; 15
Loi (CR26) 2019; 20
Rafiq, Hackett, Brentjens (CR75) 2020; 17
Mittendorf (CR55) 2014; 25
Loi (CR87) 2021; 81
CR20
Hutchins (CR69) 2017; 8
Franzoi, Romano, Piccart (CR43) 2021; 32
Rugo (CR70) 2022; 40
Lewis, Chaft, Girotra, Fischer (CR53) 2020; 124
Fridman, Pagès, Sautès-Fridman, Galon (CR6) 2012; 12
Schmid (CR39) 2020; 31
Gianni (CR37) 2022; S0923-7534
C Desmedt (508_CR3) 2008; 14
S Loi (508_CR87) 2021; 81
SA Rosenberg (508_CR76) 1987; 316
ES Reisenbichler (508_CR88) 2020; 33
L Voorwerk (508_CR95) 2021; 32
JS Weber (508_CR68) 2011; 34
S Loi (508_CR26) 2019; 20
LA Emens (508_CR86) 2021; 39
JH Park (508_CR90) 2019; 30
J Cortés (508_CR18) 2019; 15
ANJ Tutt (508_CR50) 2021; 384
SM Tolaney (508_CR21) 2020; 6
MV Maus (508_CR82) 2020; 8
AE Teschendorff (508_CR2) 2007; 8
P Schmid (508_CR15) 2018; 379
S Rafiq (508_CR75) 2020; 17
S Dees (508_CR80) 2020; 19
RA Lam (508_CR61) 2021; 13
P Savas (508_CR1) 2016; 13
J O’Shaughnessy (508_CR64) 2016; 34
508_CR42
508_CR84
AB Sharabi (508_CR44) 2015; 16
508_CR83
HS Rugo (508_CR70) 2022; 40
508_CR78
J Cortes (508_CR19) 2020; 396
E Ghisoni (508_CR52) 2021; 149
D Miles (508_CR17) 2021; 32
S Goel (508_CR22) 2016; 29
MA Franzoi (508_CR43) 2021; 32
ME Dudley (508_CR74) 2003; 3
MV Dieci (508_CR41) 2022; 28
WH Fridman (508_CR6) 2012; 12
J Fuentes-Antrás (508_CR77) 2020; 10
EA Mittendorf (508_CR56) 2016; 27
C Pantelidou (508_CR28) 2019; 9
SM Domchek (508_CR29) 2020; 21
J Deng (508_CR23) 2018; 8
M Higgins (508_CR63) 2017; 162
EA Mittendorf (508_CR35) 2020; 396
R Nanda (508_CR9) 2016; 34
LF Hutchins (508_CR69) 2017; 8
G Jerusalem (508_CR46) 2022; 33
M Aldea (508_CR91) 2021; 11
T Karn (508_CR7) 2020; 31
C Solinas (508_CR10) 2017; 2
S Vinayak (508_CR30) 2019; 5
G Morad (508_CR92) 2021; 184
A De Caluwé (508_CR45) 2021; 21
LA Emens (508_CR12) 2019; 5
AL Lewis (508_CR53) 2020; 124
GT Clifton (508_CR54) 2015; 7
R Nanda (508_CR40) 2020; 6
Y Yuan (508_CR25) 2021; 154
SM Tolaney (508_CR94) 2020; 38
S Loibl (508_CR38) 2021; 39
L Seymour (508_CR89) 2017; 18
PL Bedard (508_CR85) 2022; 82
VM Chung (508_CR66) 2018; 36
KE Hutchinson (508_CR31) 2020; 26
R Nanda (508_CR11) 2017; 77
EP Winer (508_CR13) 2021; 22
B Allard (508_CR4) 2018; 52
LA Emens (508_CR27) 2020; 21
A Gray (508_CR71) 2010; 10
J Tchou (508_CR79) 2017; 5
Y Bareche (508_CR5) 2020; 112
J Huober (508_CR48) 2022; 40
508_CR20
P Schmid (508_CR34) 2022; 386
LA Emens (508_CR16) 2021; 32
J Liu (508_CR33) 2016; 6
T Kimura (508_CR67) 2013; 13
P Cortazar (508_CR32) 2014; 384
R Thomas (508_CR62) 2018; 9
S Loibl (508_CR36) 2019; 30
LA Emens (508_CR51) 2021; 9
FJ Esteva (508_CR8) 2019; 20
KN Stevens (508_CR73) 2013; 73
508_CR58
ME Gatti-Mays (508_CR65) 2020; 10
VK Tuohy (508_CR72) 2016; 8
J Huober (508_CR47) 2021; 32
EA Mittendorf (508_CR55) 2014; 25
N Masuda (508_CR49) 2017; 376
EC Morris (508_CR81) 2022; 22
HS Rugo (508_CR24) 2022; 8
EA Mittendorf (508_CR57) 2019; 25
Z You (508_CR59) 2021; 21
508_CR93
S Adams (508_CR14) 2019; 5
L Gianni (508_CR37) 2022; S0923-7534
C Wang (508_CR60) 2016; 7
P Schmid (508_CR39) 2020; 31
References_xml – volume: 8
  start-page: e001511
  year: 2020
  ident: CR82
  article-title: Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2020-001511
  contributor:
    fullname: Maus
– volume: 9
  start-page: e002597
  year: 2021
  ident: CR51
  article-title: Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2021-002597
  contributor:
    fullname: Emens
– volume: 21
  year: 2021
  ident: CR59
  article-title: Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-021-02187-1
  contributor:
    fullname: You
– volume: 3
  start-page: 666
  year: 2003
  end-page: 675
  ident: CR74
  article-title: Adoptive-cell-transfer therapy for the treatment of patients with cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc1167
  contributor:
    fullname: Rosenberg
– volume: 13
  start-page: 35
  year: 2013
  end-page: 49
  ident: CR67
  article-title: MUC1 immunotherapy is here to stay
  publication-title: Expert Opin. Biol. Ther.
  doi: 10.1517/14712598.2012.725719
  contributor:
    fullname: Finn
– ident: CR93
– volume: 8
  start-page: 56
  year: 2016
  ident: CR72
  article-title: Targeted vaccination against human α-lactalbumin for immunotherapy and primary immunoprevention of triple negative breast cancer
  publication-title: Cancers
  doi: 10.3390/cancers8060056
  contributor:
    fullname: Tuohy
– volume: 112
  start-page: 708
  year: 2020
  end-page: 719
  ident: CR5
  article-title: Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach
  publication-title: J. Natl Cancer Inst.
  doi: 10.1093/jnci/djz208
  contributor:
    fullname: Bareche
– volume: 38
  start-page: 1015
  year: 2020
  end-page: 1015
  ident: CR94
  article-title: A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1)
  publication-title: JCO
  doi: 10.1200/JCO.2020.38.15_suppl.1015
  contributor:
    fullname: Tolaney
– volume: 22
  start-page: 85
  year: 2022
  end-page: 96
  ident: CR81
  article-title: Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-021-00547-6
  contributor:
    fullname: Sadelain
– volume: 8
  start-page: 216
  year: 2018
  end-page: 233
  ident: CR23
  article-title: CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-17-0915
  contributor:
    fullname: Deng
– volume: 31
  start-page: 569
  year: 2020
  end-page: 581
  ident: CR39
  article-title: Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.01.072
  contributor:
    fullname: Schmid
– volume: 20
  start-page: e175
  year: 2019
  end-page: e186
  ident: CR8
  article-title: Immunotherapy and targeted therapy combinations in metastatic breast cancer
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(19)30026-9
  contributor:
    fullname: Pusztai
– volume: 124
  start-page: 251
  year: 2020
  end-page: 260
  ident: CR53
  article-title: Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist
  publication-title: Br. J. Anaesth.
  doi: 10.1016/j.bja.2019.11.034
  contributor:
    fullname: Fischer
– volume: 32
  start-page: 983
  year: 2021
  end-page: 993
  ident: CR16
  article-title: First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.05.355
  contributor:
    fullname: Emens
– volume: 14
  start-page: 5158
  year: 2008
  end-page: 5165
  ident: CR3
  article-title: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-4756
  contributor:
    fullname: Desmedt
– volume: 396
  start-page: 1090
  year: 2020
  end-page: 1100
  ident: CR35
  article-title: Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)31953-X
  contributor:
    fullname: Mittendorf
– ident: CR58
– ident: CR84
– volume: 29
  start-page: 255
  year: 2016
  end-page: 269
  ident: CR22
  article-title: Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.02.006
  contributor:
    fullname: Goel
– volume: 21
  start-page: 1283
  year: 2020
  end-page: 1295
  ident: CR27
  article-title: trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30465-4
  contributor:
    fullname: Emens
– ident: CR42
– volume: 184
  start-page: 5309
  year: 2021
  end-page: 5337
  ident: CR92
  article-title: Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
  publication-title: Cell
  doi: 10.1016/j.cell.2021.09.020
  contributor:
    fullname: Wargo
– volume: 12
  start-page: 298
  year: 2012
  end-page: 306
  ident: CR6
  article-title: The immune contexture in human tumours: impact on clinical outcome
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3245
  contributor:
    fullname: Galon
– volume: 31
  start-page: 1216
  year: 2020
  end-page: 1222
  ident: CR7
  article-title: Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.05.015
  contributor:
    fullname: Karn
– volume: 379
  start-page: 2108
  year: 2018
  end-page: 2121
  ident: CR15
  article-title: Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1809615
  contributor:
    fullname: Schmid
– volume: 10
  start-page: 605633
  year: 2020
  ident: CR77
  article-title: Adoptive cell therapy in breast cancer: a current perspective of next-generation medicine
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.605633
  contributor:
    fullname: Fuentes-Antrás
– volume: 5
  start-page: 1132
  year: 2019
  end-page: 1140
  ident: CR30
  article-title: Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2019.1029
  contributor:
    fullname: Vinayak
– volume: 162
  start-page: 479
  year: 2017
  end-page: 488
  ident: CR63
  article-title: Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-017-4130-y
  contributor:
    fullname: Higgins
– volume: 39
  start-page: 506
  year: 2021
  end-page: 506
  ident: CR38
  article-title: Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)
  publication-title: JCO
  doi: 10.1200/JCO.2021.39.15_suppl.506
  contributor:
    fullname: Loibl
– volume: 21
  year: 2021
  ident: CR45
  article-title: Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial
  publication-title: BMC Cancer
  doi: 10.1186/s12885-021-08601-1
  contributor:
    fullname: De Caluwé
– volume: 34
  start-page: 556
  year: 2011
  end-page: 567
  ident: CR68
  article-title: A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e3182280db1
  contributor:
    fullname: Weber
– ident: CR78
– volume: 16
  start-page: e498
  year: 2015
  end-page: e509
  ident: CR44
  article-title: Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(15)00007-8
  contributor:
    fullname: Drake
– volume: 32
  start-page: 1061
  year: 2021
  end-page: 1062
  ident: CR47
  article-title: VP6-2021: IMpassion050: a phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.05.800
  contributor:
    fullname: Huober
– volume: 8
  start-page: 99161
  year: 2017
  end-page: 99178
  ident: CR69
  article-title: Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.21959
  contributor:
    fullname: Hutchins
– volume: 34
  start-page: 1086
  year: 2016
  end-page: 1086
  ident: CR64
  article-title: Safety and initial clinical efficacy of a dendritic cell (DC) vaccine in locally advanced, triple-negative breast cancer (TNBC) patients (pts)
  publication-title: JCO
  doi: 10.1200/JCO.2016.34.15_suppl.1086
  contributor:
    fullname: O’Shaughnessy
– volume: 6
  start-page: 1598
  year: 2020
  end-page: 1605
  ident: CR21
  article-title: Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive, ERBB2-negative metastatic breast cancer: a randomized clinical trial
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2020.3524
  contributor:
    fullname: Tolaney
– volume: 30
  start-page: 1279
  year: 2019
  end-page: 1288
  ident: CR36
  article-title: A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz158
  contributor:
    fullname: Loibl
– volume: 386
  start-page: 556
  year: 2022
  end-page: 567
  ident: CR34
  article-title: Event-free survival with pembrolizumab in early triple-negative breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2112651
  contributor:
    fullname: Schmid
– volume: 81
  start-page: PD14
  year: 2021
  end-page: PD14-07
  ident: CR87
  article-title: Abstract PD14-07: association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): exploratory analysis from KEYNOTE-086
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.SABCS20-PD14-07
  contributor:
    fullname: Loi
– volume: 2
  start-page: e000255
  year: 2017
  ident: CR10
  article-title: Targeting immune checkpoints in breast cancer: an update of early results
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2017-000255
  contributor:
    fullname: Solinas
– volume: 33
  start-page: 1746
  year: 2020
  end-page: 1752
  ident: CR88
  article-title: Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
  publication-title: Mod. Pathol.
  doi: 10.1038/s41379-020-0544-x
  contributor:
    fullname: Reisenbichler
– volume: 384
  start-page: 2394
  year: 2021
  end-page: 2405
  ident: CR50
  article-title: Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2105215
  contributor:
    fullname: Tutt
– volume: 25
  start-page: 1735
  year: 2014
  end-page: 1742
  ident: CR55
  article-title: Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdu211
  contributor:
    fullname: Mittendorf
– volume: 32
  start-page: S58
  year: 2021
  ident: CR95
  article-title: LBA3 Atezolizumab with carboplatin as immune induction in metastatic lobular breast cancer: first results of the GELATO-trial
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.03.212
  contributor:
    fullname: Voorwerk
– volume: 32
  start-page: 994
  year: 2021
  end-page: 1004
  ident: CR17
  article-title: Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.05.801
  contributor:
    fullname: Miles
– volume: 27
  start-page: 1241
  year: 2016
  end-page: 1248
  ident: CR56
  article-title: Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdw150
  contributor:
    fullname: Mittendorf
– volume: 52
  start-page: 1
  year: 2018
  end-page: 11
  ident: CR4
  article-title: Immuno-oncology-101: overview of major concepts and translational perspectives
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2018.02.005
  contributor:
    fullname: Allard
– volume: 36
  start-page: 206
  year: 2018
  end-page: 206
  ident: CR66
  article-title: A phase 1 study of p53MVA vaccine in combination with pembrolizumab
  publication-title: JCO
  doi: 10.1200/JCO.2018.36.5_suppl.206
  contributor:
    fullname: Chung
– volume: 149
  start-page: 153
  year: 2021
  end-page: 164
  ident: CR52
  article-title: Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2021.03.010
  contributor:
    fullname: Ghisoni
– volume: 26
  start-page: 657
  year: 2020
  end-page: 668
  ident: CR31
  article-title: Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-19-1773
  contributor:
    fullname: Hutchinson
– volume: 18
  start-page: e143
  year: 2017
  end-page: e152
  ident: CR89
  article-title: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30074-8
  contributor:
    fullname: Seymour
– volume: 396
  start-page: 1817
  year: 2020
  end-page: 1828
  ident: CR19
  article-title: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32531-9
  contributor:
    fullname: Cortes
– volume: 11
  start-page: 874
  year: 2021
  end-page: 899
  ident: CR91
  article-title: Overcoming resistance to tumor-targeted and immune-targeted therapies
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-20-1638
  contributor:
    fullname: Aldea
– volume: 7
  start-page: 1159
  year: 2015
  end-page: 1168
  ident: CR54
  article-title: Adjuvant HER2/neu peptide cancer vaccines in breast cancer
  publication-title: Immunotherapy
  doi: 10.2217/imt.15.81
  contributor:
    fullname: Peoples
– volume: 34
  start-page: 2460
  year: 2016
  end-page: 2467
  ident: CR9
  article-title: Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.64.8931
  contributor:
    fullname: Nanda
– volume: 40
  start-page: 2946
  year: 2022
  end-page: 2956
  ident: CR48
  article-title: Atezolizumab with neoadjuvant anti–human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2–positive early breast cancer: primary results of the randomized phase III IMpassion050 trial
  publication-title: JCO
  doi: 10.1200/JCO.21.02772
  contributor:
    fullname: Huober
– volume: 13
  start-page: 3875
  year: 2021
  ident: CR61
  article-title: Cancer-testis antigens in triple-negative breast cancer: role and potential utility in clinical practice
  publication-title: Cancers
  doi: 10.3390/cancers13153875
  contributor:
    fullname: Lam
– volume: 10
  start-page: 581801
  year: 2020
  ident: CR65
  article-title: Improving the odds in advanced breast cancer with combination immunotherapy: stepwise addition of vaccine, immune checkpoint inhibitor, chemotherapy, and HDAC inhibitor in advanced stage breast cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.581801
  contributor:
    fullname: Gatti-Mays
– volume: 22
  start-page: 499
  year: 2021
  end-page: 511
  ident: CR13
  article-title: Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30754-3
  contributor:
    fullname: Winer
– volume: S0923-7534
  start-page: 00113
  year: 2022
  end-page: 2
  ident: CR37
  article-title: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study
  publication-title: Ann. Oncol.
  contributor:
    fullname: Gianni
– volume: 9
  start-page: 722
  year: 2019
  end-page: 737
  ident: CR28
  article-title: PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-1218
  contributor:
    fullname: Pantelidou
– volume: 73
  start-page: 2025
  year: 2013
  end-page: 2030
  ident: CR73
  article-title: Genetic susceptibility to triple-negative breast cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-12-1699
  contributor:
    fullname: Couch
– volume: 5
  start-page: 1152
  year: 2017
  end-page: 1161
  ident: CR79
  article-title: Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-17-0189
  contributor:
    fullname: Tchou
– volume: 33
  start-page: S165
  year: 2022
  end-page: S166
  ident: CR46
  article-title: 92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) primary breast cancer (BC): CheckMate 7A8
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2022.03.108
  contributor:
    fullname: Jerusalem
– volume: 30
  start-page: 1941
  year: 2019
  end-page: 1949
  ident: CR90
  article-title: Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz395
  contributor:
    fullname: Park
– volume: 39
  start-page: 1006
  year: 2021
  end-page: 1006
  ident: CR86
  article-title: The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130
  publication-title: JCO
  doi: 10.1200/JCO.2021.39.15_suppl.1006
  contributor:
    fullname: Emens
– volume: 13
  start-page: 228
  year: 2016
  end-page: 241
  ident: CR1
  article-title: Clinical relevance of host immunity in breast cancer: from TILs to the clinic
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2015.215
  contributor:
    fullname: Savas
– volume: 6
  start-page: 1382
  year: 2016
  end-page: 1399
  ident: CR33
  article-title: Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-16-0577
  contributor:
    fullname: Liu
– volume: 82
  start-page: P2-13
  year: 2022
  end-page: P2-107
  ident: CR85
  article-title: Abstract P2-13-07: zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.SABCS21-P2-13-07
  contributor:
    fullname: Bedard
– volume: 6
  start-page: 676
  year: 2020
  end-page: 684
  ident: CR40
  article-title: Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 Trial
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2019.6650
  contributor:
    fullname: Nanda
– volume: 19
  start-page: 2409
  year: 2020
  end-page: 2421
  ident: CR80
  article-title: Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-20-0385
  contributor:
    fullname: Grewal
– volume: 32
  start-page: 323
  year: 2021
  end-page: 336
  ident: CR43
  article-title: Immunotherapy for early breast cancer: too soon, too superficial, or just right?
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.11.022
  contributor:
    fullname: Piccart
– volume: 21
  start-page: 1155
  year: 2020
  end-page: 1164
  ident: CR29
  article-title: Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30324-7
  contributor:
    fullname: Domchek
– volume: 154
  start-page: 11
  year: 2021
  end-page: 20
  ident: CR25
  article-title: Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2021.05.035
  contributor:
    fullname: Yuan
– volume: 77
  start-page: P6-P6-10
  year: 2017
  end-page: P6-P6-103
  ident: CR11
  article-title: Abstract P6-10-03: KEYNOTE-012: long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.SABCS16-P6-10-03
  contributor:
    fullname: Nanda
– volume: 5
  start-page: 74
  year: 2019
  end-page: 82
  ident: CR12
  article-title: Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2018.4224
  contributor:
    fullname: Emens
– volume: 7
  year: 2016
  ident: CR60
  article-title: Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms10499
  contributor:
    fullname: Wang
– volume: 15
  start-page: 1951
  year: 2019
  end-page: 1961
  ident: CR18
  article-title: IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer
  publication-title: Future Oncol.
  doi: 10.2217/fon-2019-0059
  contributor:
    fullname: Cortés
– volume: 40
  start-page: TPS611
  year: 2022
  end-page: TPS611
  ident: CR70
  article-title: A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer
  publication-title: JCO
  doi: 10.1200/JCO.2022.40.16_suppl.TPS611
  contributor:
    fullname: Rugo
– volume: 376
  start-page: 2147
  year: 2017
  end-page: 2159
  ident: CR49
  article-title: Adjuvant capecitabine for breast cancer after preoperative chemotherapy
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1612645
  contributor:
    fullname: Masuda
– volume: 8
  year: 2007
  ident: CR2
  article-title: An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer
  publication-title: Genome Biol.
  doi: 10.1186/gb-2007-8-8-r157
  contributor:
    fullname: Caldas
– volume: 25
  start-page: 4248
  year: 2019
  end-page: 4254
  ident: CR57
  article-title: Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-2867
  contributor:
    fullname: Mittendorf
– volume: 384
  start-page: 164
  year: 2014
  end-page: 172
  ident: CR32
  article-title: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)62422-8
  contributor:
    fullname: Cortazar
– ident: CR83
– volume: 9
  start-page: 947
  year: 2018
  ident: CR62
  article-title: NY-ESO-1 based immunotherapy of cancer: current perspectives
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.00947
  contributor:
    fullname: Thomas
– volume: 10
  start-page: 197
  year: 2010
  end-page: 203
  ident: CR71
  article-title: Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting
  publication-title: Mol. Inter.
  doi: 10.1124/mi.10.4.2
  contributor:
    fullname: Kast
– volume: 17
  start-page: 147
  year: 2020
  end-page: 167
  ident: CR75
  article-title: Engineering strategies to overcome the current roadblocks in CAR T cell therapy
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-019-0297-y
  contributor:
    fullname: Brentjens
– volume: 5
  start-page: 334
  year: 2019
  end-page: 342
  ident: CR14
  article-title: Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2018.5152
  contributor:
    fullname: Adams
– volume: 28
  start-page: 308
  year: 2022
  end-page: 317
  ident: CR41
  article-title: Neoadjuvant chemotherapy and immunotherapy in luminal B-like breast cancer: results of the phase II GIADA trial
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-2260
  contributor:
    fullname: Dieci
– ident: CR20
– volume: 20
  start-page: 371
  year: 2019
  end-page: 382
  ident: CR26
  article-title: Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(18)30812-X
  contributor:
    fullname: Loi
– volume: 8
  year: 2022
  ident: CR24
  article-title: Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: phase 1b study
  publication-title: NPJ Breast Cancer
  doi: 10.1038/s41523-022-00482-2
  contributor:
    fullname: Rugo
– volume: 316
  start-page: 889
  year: 1987
  end-page: 897
  ident: CR76
  article-title: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM198704093161501
  contributor:
    fullname: Rosenberg
– ident: 508_CR58
  doi: 10.1136/jitc-2020-SITC2020.0320
– volume: 11
  start-page: 874
  year: 2021
  ident: 508_CR91
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-20-1638
  contributor:
    fullname: M Aldea
– volume: 32
  start-page: 994
  year: 2021
  ident: 508_CR17
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.05.801
  contributor:
    fullname: D Miles
– volume: 3
  start-page: 666
  year: 2003
  ident: 508_CR74
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc1167
  contributor:
    fullname: ME Dudley
– volume: 39
  start-page: 1006
  year: 2021
  ident: 508_CR86
  publication-title: JCO
  doi: 10.1200/JCO.2021.39.15_suppl.1006
  contributor:
    fullname: LA Emens
– volume: 31
  start-page: 1216
  year: 2020
  ident: 508_CR7
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.05.015
  contributor:
    fullname: T Karn
– volume: 8
  start-page: 99161
  year: 2017
  ident: 508_CR69
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.21959
  contributor:
    fullname: LF Hutchins
– volume: 18
  start-page: e143
  year: 2017
  ident: 508_CR89
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30074-8
  contributor:
    fullname: L Seymour
– volume: 33
  start-page: 1746
  year: 2020
  ident: 508_CR88
  publication-title: Mod. Pathol.
  doi: 10.1038/s41379-020-0544-x
  contributor:
    fullname: ES Reisenbichler
– volume: 15
  start-page: 1951
  year: 2019
  ident: 508_CR18
  publication-title: Future Oncol.
  doi: 10.2217/fon-2019-0059
  contributor:
    fullname: J Cortés
– volume: 6
  start-page: 676
  year: 2020
  ident: 508_CR40
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2019.6650
  contributor:
    fullname: R Nanda
– volume: 73
  start-page: 2025
  year: 2013
  ident: 508_CR73
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-12-1699
  contributor:
    fullname: KN Stevens
– volume: 2
  start-page: e000255
  year: 2017
  ident: 508_CR10
  publication-title: ESMO Open
  doi: 10.1136/esmoopen-2017-000255
  contributor:
    fullname: C Solinas
– volume: 9
  start-page: 947
  year: 2018
  ident: 508_CR62
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.00947
  contributor:
    fullname: R Thomas
– volume: 5
  start-page: 1132
  year: 2019
  ident: 508_CR30
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2019.1029
  contributor:
    fullname: S Vinayak
– volume: 6
  start-page: 1382
  year: 2016
  ident: 508_CR33
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-16-0577
  contributor:
    fullname: J Liu
– volume: 21
  year: 2021
  ident: 508_CR59
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-021-02187-1
  contributor:
    fullname: Z You
– volume: 7
  year: 2016
  ident: 508_CR60
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms10499
  contributor:
    fullname: C Wang
– volume: 316
  start-page: 889
  year: 1987
  ident: 508_CR76
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM198704093161501
  contributor:
    fullname: SA Rosenberg
– volume: 22
  start-page: 85
  year: 2022
  ident: 508_CR81
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-021-00547-6
  contributor:
    fullname: EC Morris
– volume: 81
  start-page: PD14
  year: 2021
  ident: 508_CR87
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.SABCS20-PD14-07
  contributor:
    fullname: S Loi
– volume: 36
  start-page: 206
  year: 2018
  ident: 508_CR66
  publication-title: JCO
  doi: 10.1200/JCO.2018.36.5_suppl.206
  contributor:
    fullname: VM Chung
– volume: 19
  start-page: 2409
  year: 2020
  ident: 508_CR80
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-20-0385
  contributor:
    fullname: S Dees
– volume: 5
  start-page: 74
  year: 2019
  ident: 508_CR12
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2018.4224
  contributor:
    fullname: LA Emens
– volume: 8
  year: 2022
  ident: 508_CR24
  publication-title: NPJ Breast Cancer
  doi: 10.1038/s41523-022-00482-2
  contributor:
    fullname: HS Rugo
– volume: S0923-7534
  start-page: 00113
  year: 2022
  ident: 508_CR37
  publication-title: Ann. Oncol.
  contributor:
    fullname: L Gianni
– volume: 77
  start-page: P6-P6-10
  year: 2017
  ident: 508_CR11
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.SABCS16-P6-10-03
  contributor:
    fullname: R Nanda
– volume: 20
  start-page: 371
  year: 2019
  ident: 508_CR26
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(18)30812-X
  contributor:
    fullname: S Loi
– volume: 384
  start-page: 164
  year: 2014
  ident: 508_CR32
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)62422-8
  contributor:
    fullname: P Cortazar
– volume: 162
  start-page: 479
  year: 2017
  ident: 508_CR63
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-017-4130-y
  contributor:
    fullname: M Higgins
– volume: 34
  start-page: 2460
  year: 2016
  ident: 508_CR9
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.64.8931
  contributor:
    fullname: R Nanda
– volume: 21
  start-page: 1155
  year: 2020
  ident: 508_CR29
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30324-7
  contributor:
    fullname: SM Domchek
– volume: 5
  start-page: 1152
  year: 2017
  ident: 508_CR79
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-17-0189
  contributor:
    fullname: J Tchou
– volume: 8
  start-page: 56
  year: 2016
  ident: 508_CR72
  publication-title: Cancers
  doi: 10.3390/cancers8060056
  contributor:
    fullname: VK Tuohy
– ident: 508_CR83
  doi: 10.1016/j.trecan.2020.09.004
– volume: 22
  start-page: 499
  year: 2021
  ident: 508_CR13
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30754-3
  contributor:
    fullname: EP Winer
– volume: 396
  start-page: 1090
  year: 2020
  ident: 508_CR35
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)31953-X
  contributor:
    fullname: EA Mittendorf
– volume: 33
  start-page: S165
  year: 2022
  ident: 508_CR46
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2022.03.108
  contributor:
    fullname: G Jerusalem
– volume: 28
  start-page: 308
  year: 2022
  ident: 508_CR41
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-2260
  contributor:
    fullname: MV Dieci
– volume: 17
  start-page: 147
  year: 2020
  ident: 508_CR75
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-019-0297-y
  contributor:
    fullname: S Rafiq
– volume: 52
  start-page: 1
  year: 2018
  ident: 508_CR4
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2018.02.005
  contributor:
    fullname: B Allard
– volume: 25
  start-page: 4248
  year: 2019
  ident: 508_CR57
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-2867
  contributor:
    fullname: EA Mittendorf
– volume: 21
  year: 2021
  ident: 508_CR45
  publication-title: BMC Cancer
  doi: 10.1186/s12885-021-08601-1
  contributor:
    fullname: A De Caluwé
– volume: 112
  start-page: 708
  year: 2020
  ident: 508_CR5
  publication-title: J. Natl Cancer Inst.
  doi: 10.1093/jnci/djz208
  contributor:
    fullname: Y Bareche
– volume: 20
  start-page: e175
  year: 2019
  ident: 508_CR8
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(19)30026-9
  contributor:
    fullname: FJ Esteva
– volume: 16
  start-page: e498
  year: 2015
  ident: 508_CR44
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(15)00007-8
  contributor:
    fullname: AB Sharabi
– volume: 384
  start-page: 2394
  year: 2021
  ident: 508_CR50
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2105215
  contributor:
    fullname: ANJ Tutt
– volume: 30
  start-page: 1941
  year: 2019
  ident: 508_CR90
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz395
  contributor:
    fullname: JH Park
– volume: 9
  start-page: e002597
  year: 2021
  ident: 508_CR51
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2021-002597
  contributor:
    fullname: LA Emens
– volume: 184
  start-page: 5309
  year: 2021
  ident: 508_CR92
  publication-title: Cell
  doi: 10.1016/j.cell.2021.09.020
  contributor:
    fullname: G Morad
– volume: 40
  start-page: TPS611
  year: 2022
  ident: 508_CR70
  publication-title: JCO
  doi: 10.1200/JCO.2022.40.16_suppl.TPS611
  contributor:
    fullname: HS Rugo
– volume: 7
  start-page: 1159
  year: 2015
  ident: 508_CR54
  publication-title: Immunotherapy
  doi: 10.2217/imt.15.81
  contributor:
    fullname: GT Clifton
– volume: 6
  start-page: 1598
  year: 2020
  ident: 508_CR21
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2020.3524
  contributor:
    fullname: SM Tolaney
– ident: 508_CR93
  doi: 10.1038/s41591-020-01189-2
– volume: 379
  start-page: 2108
  year: 2018
  ident: 508_CR15
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1809615
  contributor:
    fullname: P Schmid
– volume: 32
  start-page: 983
  year: 2021
  ident: 508_CR16
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.05.355
  contributor:
    fullname: LA Emens
– volume: 149
  start-page: 153
  year: 2021
  ident: 508_CR52
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2021.03.010
  contributor:
    fullname: E Ghisoni
– volume: 34
  start-page: 556
  year: 2011
  ident: 508_CR68
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e3182280db1
  contributor:
    fullname: JS Weber
– volume: 40
  start-page: 2946
  year: 2022
  ident: 508_CR48
  publication-title: JCO
  doi: 10.1200/JCO.21.02772
  contributor:
    fullname: J Huober
– volume: 124
  start-page: 251
  year: 2020
  ident: 508_CR53
  publication-title: Br. J. Anaesth.
  doi: 10.1016/j.bja.2019.11.034
  contributor:
    fullname: AL Lewis
– volume: 13
  start-page: 228
  year: 2016
  ident: 508_CR1
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2015.215
  contributor:
    fullname: P Savas
– volume: 12
  start-page: 298
  year: 2012
  ident: 508_CR6
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3245
  contributor:
    fullname: WH Fridman
– volume: 29
  start-page: 255
  year: 2016
  ident: 508_CR22
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.02.006
  contributor:
    fullname: S Goel
– volume: 34
  start-page: 1086
  year: 2016
  ident: 508_CR64
  publication-title: JCO
  doi: 10.1200/JCO.2016.34.15_suppl.1086
  contributor:
    fullname: J O’Shaughnessy
– volume: 10
  start-page: 605633
  year: 2020
  ident: 508_CR77
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.605633
  contributor:
    fullname: J Fuentes-Antrás
– volume: 32
  start-page: 1061
  year: 2021
  ident: 508_CR47
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.05.800
  contributor:
    fullname: J Huober
– volume: 13
  start-page: 3875
  year: 2021
  ident: 508_CR61
  publication-title: Cancers
  doi: 10.3390/cancers13153875
  contributor:
    fullname: RA Lam
– volume: 154
  start-page: 11
  year: 2021
  ident: 508_CR25
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2021.05.035
  contributor:
    fullname: Y Yuan
– volume: 8
  year: 2007
  ident: 508_CR2
  publication-title: Genome Biol.
  doi: 10.1186/gb-2007-8-8-r157
  contributor:
    fullname: AE Teschendorff
– ident: 508_CR78
  doi: 10.1200/JCO.21.02170
– volume: 9
  start-page: 722
  year: 2019
  ident: 508_CR28
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-1218
  contributor:
    fullname: C Pantelidou
– volume: 27
  start-page: 1241
  year: 2016
  ident: 508_CR56
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdw150
  contributor:
    fullname: EA Mittendorf
– ident: 508_CR84
  doi: 10.1080/14712598.2021.1922665
– volume: 8
  start-page: e001511
  year: 2020
  ident: 508_CR82
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2020-001511
  contributor:
    fullname: MV Maus
– volume: 5
  start-page: 334
  year: 2019
  ident: 508_CR14
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2018.5152
  contributor:
    fullname: S Adams
– volume: 25
  start-page: 1735
  year: 2014
  ident: 508_CR55
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdu211
  contributor:
    fullname: EA Mittendorf
– volume: 82
  start-page: P2-13
  year: 2022
  ident: 508_CR85
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.SABCS21-P2-13-07
  contributor:
    fullname: PL Bedard
– volume: 39
  start-page: 506
  year: 2021
  ident: 508_CR38
  publication-title: JCO
  doi: 10.1200/JCO.2021.39.15_suppl.506
  contributor:
    fullname: S Loibl
– volume: 8
  start-page: 216
  year: 2018
  ident: 508_CR23
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-17-0915
  contributor:
    fullname: J Deng
– volume: 38
  start-page: 1015
  year: 2020
  ident: 508_CR94
  publication-title: JCO
  doi: 10.1200/JCO.2020.38.15_suppl.1015
  contributor:
    fullname: SM Tolaney
– ident: 508_CR20
  doi: 10.1056/NEJMoa2202809
– volume: 31
  start-page: 569
  year: 2020
  ident: 508_CR39
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.01.072
  contributor:
    fullname: P Schmid
– volume: 376
  start-page: 2147
  year: 2017
  ident: 508_CR49
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1612645
  contributor:
    fullname: N Masuda
– volume: 10
  start-page: 197
  year: 2010
  ident: 508_CR71
  publication-title: Mol. Inter.
  doi: 10.1124/mi.10.4.2
  contributor:
    fullname: A Gray
– volume: 10
  start-page: 581801
  year: 2020
  ident: 508_CR65
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.581801
  contributor:
    fullname: ME Gatti-Mays
– volume: 396
  start-page: 1817
  year: 2020
  ident: 508_CR19
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32531-9
  contributor:
    fullname: J Cortes
– volume: 21
  start-page: 1283
  year: 2020
  ident: 508_CR27
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30465-4
  contributor:
    fullname: LA Emens
– volume: 30
  start-page: 1279
  year: 2019
  ident: 508_CR36
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz158
  contributor:
    fullname: S Loibl
– volume: 26
  start-page: 657
  year: 2020
  ident: 508_CR31
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-19-1773
  contributor:
    fullname: KE Hutchinson
– volume: 386
  start-page: 556
  year: 2022
  ident: 508_CR34
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2112651
  contributor:
    fullname: P Schmid
– volume: 13
  start-page: 35
  year: 2013
  ident: 508_CR67
  publication-title: Expert Opin. Biol. Ther.
  doi: 10.1517/14712598.2012.725719
  contributor:
    fullname: T Kimura
– volume: 14
  start-page: 5158
  year: 2008
  ident: 508_CR3
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-4756
  contributor:
    fullname: C Desmedt
– ident: 508_CR42
  doi: 10.1200/JCO.2019.37.15_suppl.TPS601
– volume: 32
  start-page: S58
  year: 2021
  ident: 508_CR95
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.03.212
  contributor:
    fullname: L Voorwerk
– volume: 32
  start-page: 323
  year: 2021
  ident: 508_CR43
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.11.022
  contributor:
    fullname: MA Franzoi
SSID ssj0001468951
Score 2.5894504
SecondaryResourceType review_article
Snippet Recent progress in immunobiology has led the way to successful host immunity enhancement against breast cancer. In triple-negative breast cancer, the...
Abstract Recent progress in immunobiology has led the way to successful host immunity enhancement against breast cancer. In triple-negative breast cancer, the...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 7
SubjectTerms 631/67/1347
692/4028/67/1347
Antigens
Biomarkers
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cancer Research
Cancer therapies
Cancer vaccines
Cell Biology
Chemotherapy
Clinical trials
Cytotoxicity
Human Genetics
Immunotherapy
Ligands
Lymphocytes
Medical prognosis
Medical research
Metastasis
Monoclonal antibodies
Oncology
Response rates
Review
Review Article
Tumors
Vaccines
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxQxDI6gB8QF8WZpi4LEDUbNJJkk0xuFVuUABx4Stygvi15mq87ugX-PnZndsjzEhcMcZpJIlh2P7dj-wtiLIpTOYHUDuQ-NbqNuQht6fJWuJOisdtQ7fP7Jfvjq3p4STM72qi-qCZvggSfGHWGYbUC5ItGR10pmZ0BAlxO02irZT39fYX4KpurpijYOfYe5S0YodzSSpaKUJT6io0PBHUtUAfv_5GX-Xiz5S8a0GqKzu-zO7EHy1xPl99iNMtxnt97POfIH7OM7avmYG6u-84uBRyo8X_FEAr465mHgVLdJOQG-BJ4mhCY-rjaoETgj88vrLszxIftydvr5zXkz35zQJPTAVk2EGKCgqoUgkgKAqKQFZUMCtEXSFgMOMJAJXUJ-gg452CB6F3tbHC5Sj9jesBzKE8ZFNs5El9GSKR1bGxWEaENIuksGzf-Cvdxw0V9OABm-JraV8xPPvaCHeO7Vgp0Qo7czCdy6fkCR-1nk_l8iX7CDjZj8rHGjlxYjH2sdDT_fDqOuUAIkDGW5rnMMQZK1SMfjSapbShRabbqea8Hsjrx3SN0dGS6-VTzuvqeoDVe-2uyMa7L-zoqn_4MV--y2rFtaNq06YHurq3U5ZDfHvH5WFeIHbpIN9A
  priority: 102
  providerName: Directory of Open Access Journals
Title Immunotherapy in breast cancer: an overview of current strategies and perspectives
URI https://link.springer.com/article/10.1038/s41523-023-00508-3
https://www.ncbi.nlm.nih.gov/pubmed/36781869
https://www.proquest.com/docview/2775877892
https://search.proquest.com/docview/2776517913
https://pubmed.ncbi.nlm.nih.gov/PMC9925769
https://doaj.org/article/7616f38e2956432d86f0f5dcf1473292
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbYHqpeEJRXoFRG4gbpJrYTO9ygD5VDEeIhcYtsxwMr0exqs3vov--Mk2xZaC8cckjsKKOZcWbGM_OZsdchk6oBrVJoKpuq3KnU5rbCW2GCh0IrQ73D51_1px_m5JRgcoqxFyYW7Xs3O2p_Xx61s1-xtnJx6adjndj088VxVZGbXE0nbIK-4R8hetxYUaVBt2FokMmkmXZkpChbiVdW0H7gHtuV-Jem45i27FGE7b_N1_y3ZPKvvGk0R2cP2P3Bj-Tve3ofsnuh3We7F0Om_BH78pEaP4b2qis-a7mj8vMV9yTm5TtuW07Vm5QZ4HPgvsdp4t1qxI7AGQ1f3PRido_Z97PTb8fn6XB-QurRD1ulDpyFgAvO2sxLAHBSaJDaekCLJHQowQCGM7bwpgRQtrHaZpVxlQ4GX5JP2E47b8MzxrOmNKUzDdozqVyunQTrtLVeFb5EJyBhb0Yu1oseJqOO6W1p6p79dUYXsb-WCftAjN7MJIjr-GC-_FkPgq51mZcgTRAYwSkpGiQxg6LxkCstRSUSdjCKqR7WXVcLjfGP1oaGX22GccVQGsS2Yb6Oc0oCJsuRjqe9VDeUjFqRML0l7y1St0dQSSMq96CUCXs7asYNWXez4vl_f-gF2xNRpUWaywO2s1quw0s26Zr1YdxYOIzL4hpPxRDV
link.rule.ids 230,315,729,782,786,866,887,2106,27933,27934,53800,53802
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbtQwcESLVHrhDQ0UMBI3SNexHdvhBqXVVnQrBEXiZtmODSu12dVm98DfYzvJluVx6cGHZBxl4pnJzHgeBnjlMGW1Fyz3daVzVhiW60JX4ZJIZ30pmIy1w-Mv4uyb_HAU2-SUQy1MStq3ZnrQXFweNNMfKbdyfmlHQ57Y6NPksKqimVyNtuBmkFeMf3PS09YK4zIYDn2JDKZy1EY1FeOVYeAy7gjuwg4N_-l4INOGRkqN-_9lbf6dNPlH5DQppOM71_yUu3C7t0DRuw58D2645j7sTPoY-wP4fBJLRvrCrJ9o2iATE9eXyEYGWbxFukEx7zPGFNDMI9t1eELtcug6EWbUaH5Vxdk-hK_HR-eH47w_eSG3wYJb5sYb7V0QVa2xpd57Q4nwVGjrgy4jwnEvfXCEdGkl957pWguNK2kq4WR4iD6C7WbWuD1AuOaSG1kHTUiZKYShXhuhtWWl5cF8yOD1sPpq3jXYUCkwTqXqyKZwHJFsimbwPhJoPTM2x043Zovvql9XJXjBPZWOBN-PUVIHFLEva-sLJiipSAb7A3lVL7GtIiJ4TkLICH65BgdZiwEU3bjZKs3hsaVZEfB43HHDGpOBmzIQG3yygeomJPBE6ufd80AGbwaOukLr_0vx5NovegG3xueTU3V6cvbxKeySJBYkL-g-bC8XK_cMttp69TwJ1S_6mSV3
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LbtQwcESLtOqF8iyBAkbiBmkS2xs73KDtqhW0qnhI3CK_Blai2dVm99C_x3aSLcvjAgcfEk-UiWcmM-N5GOCFyxm3KHiKtlIpLzRPVaEqf0mlMzgWXIba4ZOP4vyLPDoObXLWR33FpH2jpwfN98uDZvot5lbOL0025IllF2eHVRXM5CqbW8y24KaX2Zz-5KjH7RVeSm889GUyOZNZG1RViFn6kY_DruAOjJj_V4dDmTa0Umze_yeL8_fEyV-ip1EpTXb_43Nuw63eEiVvOpA7cMM1d2F01sfa78GH01A60hdoXZFpQ3RIYF8SExhl8ZqohoT8zxBbIDMkpuv0RNrl0H3CQ1gyv67mbO_D58nxp8OTtD-BITXeklumGrVC50VWqdwwRNSMCmRCGfQ6jQpXokTvEKmxkSUiV1YJlVdSV8JJ_xB7ANvNrHEPgeS2lKWW1mtExnUhNEOlhVKGj03pzYgEXg4UqOddo406BsiZrDvS1XkYgXQ1S-BtINIaMjTJjjdmi691v7a1KIsSmXTU-4CcUetRzHFsDRZcMFrRBPYHEte95LY1Fd6DEkKG6efraS9zIZCiGjdbRZgytDYrPB57HUesMRk4KgGxwSsbqG7OeL6Ifb17Pkjg1cBV12j9fSke_fOLnsHo4mhSvz89f_cYdmiUDJoWbB-2l4uVewJbrV09jXL1AzOiJ_c
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunotherapy+in+breast+cancer%3A+an+overview+of+current+strategies+and+perspectives&rft.jtitle=NPJ+breast+cancer&rft.au=Debien%2C+V%C3%A9ronique&rft.au=De+Caluw%C3%A9%2C+Alex&rft.au=Wang%2C+Xiaoxiao&rft.au=Piccart-Gebhart%2C+Martine&rft.date=2023-02-13&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2374-4677&rft.volume=9&rft.issue=1&rft_id=info:doi/10.1038%2Fs41523-023-00508-3&rft.externalDocID=10_1038_s41523_023_00508_3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2374-4677&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2374-4677&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2374-4677&client=summon